Because of this, andthe fact that synthetic agonists of PPAR-γ with good safety profiles arecurrently in use in the clinical arena, PPAR-γ has emerged as a reasonable target for the development of anti-lung cancer therapies. The gene discussed is PPARG; the disease is lung cancer.